Week Ending February 14, 2022

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis
“As there are uncertainties concerning continuation of HCC surveillance after HCV cure in patients with cirrhosis and in those with advanced fibrosis (F3), researchers herein investigated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis.”

Expression and Clinical Values of Serum miR-155 and miR-224 in Chinese Patients with HCV Infection
“Background: To investigate the expression of serum miR-155 and miR-224 among patients with hepatitis C virus (HCV) infection and analyze their clinical values.”

Opinion: New York State is ready for statewide injection sites
“After New York City successfully opened the nations’s first legally operating overdose prevention centers, it’s time to open more of them across the state.”

Liver Cancer in Hispanic and Latino Communities: What You Need to Know
“Liver cancer is cancer that starts in any part of the liver. The most common type of liver cancer is called hepatocellular carcinoma (HCC). Rates of liver cancer are going up in the United States. In men, HCC ranks as the fifth most common cause of cancer-related death. For women, it ranks seventh.”

UF Health researchers use artificial intelligence to better predict hepatitis C treatment outcomes
“When hepatitis C treatments fail, patients can face major health risks and the expense of a second therapy. Now, University of Florida Health researchers have developed algorithms that use artificial intelligence to accurately predict when treatment won’t work.”

Can Those Who Have HCV Benefit from PrEP?
“For some people with hepatitis C (HCV), lifestyle factors could put them at risk for HIV infection. Investigators from Harvard, University of Maryland, HIPS, and NIH decided to assess the potential of utilizing PrEP among individuals with HCV and associations with PrEP awareness, access, and interest.”